IL2 and lung carcinoma: Ex vivo activation of NK cells with a naturally occurring HSP70 peptide and IL-2 (TKD-IL-2) enhanced the anti-cancer ability of NK cells against lung cancer and glioblastoma in preclinical tumor models [144].